V8 Peptides — Engineered Performance
Research Library
How Selank Is Made: Synthesis Steps and Impurities
SelankChemistry

How Selank Is Made: Synthesis Steps and Impurities

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Selank is made by stepwise solid-phase synthesis, then cleaved, purified and freeze-dried. Each stage can leave a characteristic impurity: deletion peptides, stereoisomers, residual protecting groups or counter-ion. Proline-rich sequences can also give split HPLC peaks that are not impurities. A useful certificate shows the sequence, lot, method, chromatogram and observed mass. This explainer describes the general route, not any specific lot. Supplied for laboratory research use only.

Selank looks simple on paper: seven residues, Thr-Lys-Pro-Arg-Pro-Gly-Pro, no disulfide, no unusual amino acids. A short sequence does not mean a trivial synthesis, though, and it does not mean every vial is the same. This article walks through how a heptapeptide like this is made by chemical synthesis, where each step can leave an impurity, and what a laboratory should look for in the documentation to confirm that the material matches the sequence. It is a chemistry explainer for researchers. The Selank product page lists the material as a 10 mg lyophilized powder with the formula C33H57N11O9 and a ≥98% HPLC specification, supplied for laboratory research use only.

V8 Peptides does not publish its manufacturer's batch records, so what follows is a general description of the standard route and its known risks, not a description of any particular lot. For the compound background see the Selank research overview and what is Selank; for how sequences are written and read, understanding amino acid sequences.

Where the sequence comes from

The first four residues, Thr-Lys-Pro-Arg, are the sequence of tuftsin, a natural tetrapeptide whose chemical synthesis and biological properties were described in 1973 (Nishioka and colleagues, 1973). The product page describes Selank as a synthetic tuftsin analog in which a Pro-Gly-Pro tail was added to make the molecule more resistant to peptidase breakdown. The Pro-Gly-Pro tail is the reason the compound is a heptapeptide and not a tetrapeptide. From a synthetic point of view the tail matters because it places proline at both positions 5 and 7, and proline-rich sequences have their own behaviours during assembly and analysis.

The standard route: Fmoc solid-phase synthesis

Peptides of this length are normally made by solid-phase peptide synthesis, in which the chain is built from the C-terminus to the N-terminus on an insoluble resin. A widely used protocol based on the Fmoc/tBu strategy, with aminium-type coupling reagents, is described in detail in the methods literature (Coin and colleagues, 2007), and the broader field of Fmoc chemistry has been reviewed (Behrendt and colleagues, 2016). The overall plan for Selank is:

  1. Anchor the C-terminal proline to the resin. Selank ends in a free acid, not an amide, so the resin type must release a carboxylic acid on cleavage.
  2. Deprotect and couple, residue by residue: glycine, proline, arginine, proline, lysine, threonine. Side chains of arginine, lysine and threonine carry protecting groups that survive the cycles and are removed at the end.
  3. Remove the N-terminal protecting group from threonine.
  4. Cleave from the resin with a strong acid mixture containing scavengers, which also removes the side-chain protecting groups.
  5. Precipitate, dissolve and purify by preparative reversed-phase HPLC.
  6. Exchange the counter-ion if required, and lyophilize.
  7. Analyse by analytical HPLC and mass spectrometry.

Large-scale chemical synthesis of peptides follows the same logic with the engineering concerns of scale (Bray, 2003), and drug-discovery reviews place short, stable peptides such as this one among the more accessible synthetic targets (Muttenthaler and colleagues, 2021).

Where impurities can enter, step by step

StepWhat can go wrongImpurity producedDoes HPLC alone find it?
Loading the first prolineLow or uneven loading; partial racemizationReduced yield; a diastereomerDiastereomer may co-elute
Coupling of a residueIncomplete reactionDeletion peptide missing one residueUsually yes, different retention
Early dipeptide stageLoss of the first two residues from the resin as a cyclic dipeptideLower yield; a truncated chain on the resinCyclic product is removed in washes
Arginine couplingSlow acylation of the bulky protected residueDeletion peptide missing arginineUsually yes
Final cleavageIncomplete removal of a protecting groupAdduct with extra massYes, by mass
PurificationImpurities with near-identical retentionCo-eluting contaminantNo; needs a second method
Counter-ion handlingResidual trifluoroacetateSalt form, not a peptide impurityNo; needs ion analysis

A few of these deserve explanation.

Dipeptide loss. In Fmoc synthesis, a dipeptide attached to the resin can curl back and cleave itself off as a cyclic dipeptide when the second residue is proline or glycine. This is a recognised side reaction in general, and a sequence that ends in Gly-Pro at the C-terminus is the kind of case where a synthetic chemist chooses the resin and the conditions to limit it. The practical consequence for a buyer is limited, because the loss reduces yield rather than producing an impurity in the finished vial, but it is a reason that short sequences are not always cheap to make well.

Deletion peptides. If a coupling is incomplete and not capped, the next residue is added to the unreacted chain and the finished peptide lacks one residue. For Selank a six-residue deletion product would differ from the target by the mass of one amino acid. A deletion lacking proline differs by about 97 Da, one lacking arginine by about 156 Da, one lacking glycine by about 57 Da. Mass spectrometry distinguishes them from the target easily, and reversed-phase HPLC generally resolves them as separate peaks, which is why a clean chromatogram is meaningful for a sequence of this length.

Stereochemical impurities. A diastereomer has the same mass as the target. Proline-rich peptides can also show split or broadened HPLC peaks because of slow cis–trans isomerization of the peptide bond, which means extra peaks are not always impurities. Resolving the two explanations needs a second method or a different temperature.

Counter-ions and what "10 mg" means

Purification by reversed-phase HPLC typically uses trifluoroacetic acid, so the isolated peptide is usually a trifluoroacetate salt unless it has been exchanged for another counter-ion (Sikora and colleagues, 2020). Selank has three basic sites (lysine, arginine and the N-terminal amine), so the salt can account for a substantial fraction of the powder weight. The declared 10 mg is a mass of material, and the peptide content may be lower. Where the work is quantitative or in cell culture, the salt form is a variable: one study reported that trifluoroacetate in purified peptide preparations inhibited proliferation of osteoblasts and chondrocytes in culture (Cornish and colleagues, 1999). The concentration formulas are c = m / V and cM = (m / MW) / V, with m multiplied by peptide content p where reported; the calculator automates the first.

What the quality documentation should show

Document elementWhy it matters for a synthetic heptapeptide
Sequence and formula matching Thr-Lys-Pro-Arg-Pro-Gly-Pro, C33H57N11O9Confirms the intended molecule
Lot number identical to the vialTies the analysis to the material
HPLC method, chromatogram and purityShows whether deletion peptides and other peaks are resolved
Observed massRules out deletion products and adducts
Test datePlaces the analysis in time
Salt form or peptide content, if reportedNeeded for exact molar work

Published work on Selank itself sometimes notes how its material was checked. A 2018 study of the peptide's molecular activity states that HPLC was used to obtain and ensure the purity of reagents including Selank (Vyunova and colleagues, 2018), a reminder that analytical verification is part of the experiment and not a formality. Our own certificate pages are listed on the COA page, and the reading skills are in how to read a COA and Selank purity testing.

Why lyophilization is the last step

After purification the peptide is in a water–acetonitrile mixture. Freeze-drying removes the solvent and leaves a porous cake that is stable for storage and quick to dissolve; the process is explained in what is lyophilization. The cake can still hold residual water and counter-ion, which is another reason the declared mass and the peptide mass can differ. On receipt, keep the vial as the product page instructs: 2–8 °C, −20 °C for a long hold, protected from heat, moisture and light. Reconstitution is covered in how to reconstitute a lyophilized peptide.

What this article does not claim

None of the sources cited describes the synthesis of any commercial lot of Selank, and the table of impurity types describes general risks, not measured contents of any vial. Where the identity or purity of the material matters to your result, read the lot certificate, run your own check if you can, and record what you find.

Related reading

Frequently asked questions

How is Selank made?

Peptides of this length are normally made by Fmoc solid-phase synthesis: the chain is assembled from the C-terminus on a resin, cleaved with strong acid, purified by reversed-phase HPLC, exchanged into the chosen counter-ion and freeze-dried.

What is the sequence of Selank?

Thr-Lys-Pro-Arg-Pro-Gly-Pro, with the formula C33H57N11O9, as listed on the product page. The first four residues are the sequence of tuftsin.

Why is a short peptide not always easy to synthesize?

Each coupling is imperfect and proline-rich or Gly-Pro-terminated sequences are prone to specific side reactions, so the chemist has to choose the resin and conditions carefully.

What is a deletion peptide?

A product missing one residue because a coupling step failed. It has a different mass and usually a different retention time, so mass spectrometry and a clean chromatogram can reveal it.

Why can a proline-rich peptide show an extra HPLC peak?

Slow cis–trans isomerization at proline peptide bonds can broaden or split a peak, so an extra peak is not always an impurity. A second method or a different temperature helps decide.

Why is the declared mass not the same as peptide mass?

Counter-ion, residual water and other salts account for part of the powder weight. Selank has three basic sites, so a salt can be a substantial fraction.

What is trifluoroacetate?

It is the counter-ion left from HPLC purification with trifluoroacetic acid. One study reported it inhibited proliferation of osteoblasts and chondrocytes in culture, so it matters in cell-based work.

Does mass spectrometry prove the sequence?

It proves the composition. Peptides with the same residues in another order share a mass, so order needs fragmentation data or a reference standard.

Where can I see a lot certificate?

The COA page lists published certificates. The product page says to check the COA page for this product's status and to file a copy with receiving records.

Is Selank from V8 for use in people or animals?

No. It is sold strictly for laboratory research use only.

Related reading: Nootropic Peptides: Semax and Selank Evidence Map, Selank in Animal Models: Preclinical Findings Reviewed, Selank Quality Control: Purity and Identity Checks.

References

  1. Nishioka K, Constantopoulos A, Satoh PS, Najjar VA. The chemical synthesis of the phagocytosis-stimulating tetrapeptide tuftsin (Thr-Lys-Pro-Arg) and its biologic properties. Biochim Biophys Acta. 1973;310(1):217-229. doi:10.1016/0005-2795(73)90025-1
  2. Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247-3256. doi:10.1038/nprot.2007.454
  3. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836
  4. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587-593. doi:10.1038/nrd1133
  5. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8
  6. Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals (Basel). 2020;13(12):442. doi:10.3390/ph13120442
  7. Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.e779
  8. Vyunova TV, Andreeva LA, Shevchenko KV, et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018;25(10):914-922. doi:10.2174/0929866525666180925144642

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.